This phase I trial studies how well lorcaserin works in treating chemotherapy-induced peripheral neuropathy in patients with stage I-IV gastrointestinal or breast cancer. Chemotherapy-induced peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. This condition can occur in patients who have received taxane chemotherapy drugs, or the chemotherapy drug oxaliplatin. Lorcaserin may improve chemotherapy-induced peripheral neuropathy by reducing pain, preventing or relieving joint symptoms, and improving balance.

Start Date01 Nov 2020

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

NCT04572243 / TerminatedPhase 3

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.

Start Date23 Sep 2020

Sponsor / Collaborator

Eisai, Inc.

NCT04396847 / TerminatedPhase 2IIT

Human Laboratory Screening of Lorcaserin in Smokers With Alcohol Use Disorder

Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventions, there are presently no approved medications for the joint indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin system plays a role in alcohol and nicotine consumption and relapse, this study aims to examine whether a serotonin medication alters alcohol and nicotine responses in smokers with AUD, informing its potential utility as a candidate therapy for this clinical subgroup.

Start Date25 Oct 2019

Sponsor / Collaborator

The Mind Research Network

100 Clinical Results associated with Lorcaserin Hydrochloride

100 Translational Medicine associated with Lorcaserin Hydrochloride

100 Patents (Medical) associated with Lorcaserin Hydrochloride

447

Literatures (Medical) associated with Lorcaserin Hydrochloride

01 Dec 2024·NEUROPHARMACOLOGY

Activation of ventral pallidum-projecting neurons in the nucleus accumbens via 5-HT2C receptor stimulation regulates motivation for wheel running in male mice

Article

Author: Nishitani, Naoya ; Futami, Yusaku ; Kaneda, Katsuyuki ; Nishida, Ryoma ; Niitani, Kazuhei ; Deyama, Satoshi

Rodents have a strong motivation for wheel running; however, the neural mechanisms that regulate their motivation remain unknown. We investigated the possible involvement of serotonin (5-HT) systems in regulating motivation for wheel running in male mice. Systemic administration of a 5-HT_1A receptor antagonist (WAY100635) increased the number of wheel rotations, whereas administration of a 5-HT_2A or 5-HT_2C receptor antagonist (volinanserin or SB242084, respectively) decreased it. In the open field test, neither WAY100635 nor volinanserin affected locomotor activity, whereas SB242084 increased locomotor activity. To identify the brain regions on which these antagonists act, we locally injected these into the motivational circuitry, including the nucleus accumbens (NAc), dorsomedial striatum (DM-Str), and medial prefrontal cortex (mPFC). Injection of SB242084 into the NAc, but not the DM-Str or mPFC, reduced the number of wheel rotations without altering locomotor activity. The local administration of WAY100635 or volinanserin to these brain regions did not affect the number of wheel rotations. Immunohistochemical analyses revealed that wheel running increased the number of c-Fos-positive cells in the NAc medial shell (NAc-MS), which was reduced by systemic SB242084 administration. In vitro slice whole-cell recordings showed that bath application of the 5-HT_2C receptor agonist lorcaserin increased the frequency of spontaneous excitatory and inhibitory postsynaptic currents in the ventral tegmental area (VTA)-projecting neurons, whereas it only increased the frequency of spontaneous excitatory postsynaptic currents in ventral pallidum (VP)-projecting neurons in the NAc-MS. These findings suggest that the activation of VP-projecting NAc-MS neurons via 5-HT_2C receptor stimulation regulates motivation for wheel running.

01 Dec 2024·REGULATORY TOXICOLOGY AND PHARMACOLOGY

Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells

Article

Author: Heflich, Robert H. ; Atrakchi, Aisar H ; McGovern, Timothy J. ; Keire, David A. ; Atrakchi, Aisar H. ; Heflich, Robert H ; Le, Yuan ; Mei, Nan ; McGovern, Timothy J ; Davis-Bruno, Karen L ; Dorsam, Robert T ; Guo, Xiaoqing ; King, Sruthi T. ; King, Sruthi T ; Li, Xilin ; Dorsam, Robert T. ; Keire, David A ; Davis-Bruno, Karen L.

Nitrosamine drug substance-related impurities (NDSRIs) are a sub-category of N-nitrosamine drug impurities that share structural similarity to the corresponding active pharmaceutical ingredient. The mutagenicity of NDSRIs is poorly understood. We previously tested a series of NDSRIs using the Enhanced Ames Test (EAT). In this follow-up study, we further examined the genotoxicity and mutagenicity of 15 of these NDSRIs in human TK6 cells. Seven EAT-positive NDSRIs, including N-nitroso-nortriptyline, N-nitroso-fluoxetine, N-nitroso-desmethyl-diphenhydramine, N-nitroso-duloxetine, N-nitroso-lorcaserin, N-nitroso-varenicline, and N-nitroso-sertraline, induced concentration-dependent increases in micronuclei after bioactivation with hamster liver S9. These NDSRIs were also mutagenic in the TK and HPRT gene mutation assays, consistent with their positive EAT results. In the presence of hamster liver S9, the eight EAT-negative NDSRIs were negative in the micronucleus assay and negative for mutation induction. Using TK6 cells endogenously expressing a single human cytochrome P450 (CYP), we found that CYP2C19, CYP2B6, CYP2A6, and CYP3A4 are key enzymes activating the genotoxicity and mutagenicity of these NDSRIs. Overall, the hamster S9-mediated TK6 cell mutagenicity results agreed with those observed in the EAT, indicating consistency in the mutagenic responses produced by NDSRIs across different testing systems. These data support the use of EAT for hazard identification and safety assessment of NDSRIs.

01 Oct 2024·EPILEPSIA

Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome

Article

Author: Reilly, Christopher A. ; Mensah, Jeffrey A. ; Metcalf, Cameron S. ; Wilcox, Karen S. ; Rower, Joseph E. ; Johnson, Kristina ; Freeman, Tia

Abstract:

Objective:

The current standard of care for Dravet syndrome (DS) includes polytherapy after inadequate seizure control with one or more monotherapy approaches. Treatment guidelines are often based on expert opinions, and finding an optimal balance between seizure control and adverse drug effects can be challenging. This study utilizes the efficacy and pharmacokinetic assessment of a second‐line treatment regimen that combines clobazam and sodium valproate with an add‐on drug as a proof‐of‐principle approach to establish an effective therapeutic regimen in a DS mouse model.

Methods:

We evaluated the efficacy of add‐on therapies stiripentol, cannabidiol, lorcaserin, or fenfluramine added to clobazam and sodium valproate against hyperthermia‐induced seizures in Scn1aA1783V/WT mice. Clobazam, N‐desmethyl clobazam (an active metabolite of clobazam), sodium valproate, stiripentol, and cannabidiol concentrations were quantified in plasma and brain using liquid chromatography–tandem mass spectrometry for the combinations deemed effective against hyperthermia‐induced seizures. The concentration data were used to calculate pharmacokinetic parameters via noncompartmental analysis in Phoenix WinNonLin.

Results:

Higher doses of stiripentol or cannabidiol, in combination with clobazam and sodium valproate, were effective against hyperthermia‐induced seizures in Scn1aA1783V/WT mice. In Scn1aWT/WT mice, brain clobazam and N‐desmethyl clobazam concentrations were higher in the triple‐drug combinations than in the clobazam monotherapy. Stiripentol and cannabidiol brain concentrations were greater in the triple‐drug therapy than when given alone.

Significance:

A polypharmacy strategy may be a practical preclinical approach to identifying efficacious compounds for DS. The drug–drug interactions between compounds used in this study may explain the potentiated efficacy of some polytherapies.

News (Medical) associated with Lorcaserin Hydrochloride

18 Nov 2024

·firstwordpharma.com

Eisai officially winds down epilepsy programme

Eisai has shuttered a pair of clinical trials evaluating lorcaserin to treat Dravet syndrome after struggling to recruit enough patients with the rare form of epilepsy. The discontinuations, first disclosed in August by the Dravet Syndrome Foundation, affect the Phase III MOMENTUM 1 study and the MOMENTUM 2 extended access programme. "As other FDA-approved therapies have become available to treat this complex condition, recruiting patients for an investigational therapy has been exceedingly challenging," an Eisai spokesperson told FirstWord.The trials may have suffered from unfortunate timing, as they launched around the same time that a new drug with a similar mechanism of action hit shelves. Zogenix won FDA approval in 2020 for Fintepla (fenfluramine), a serotonin releasing agent, to treat Dravet syndrome; the drugmaker was then bought by UCB for $1.9 billion in 2022. According to the disease foundation's August release, "Just as the studies for lorcaserin began, many patients were trying the newly available Fintepla for the first time, which may have been a factor in the difficulties enrolling enough participants in the study."Earlier this year, FirstWord spoke with a dozen key opinion leaders (KOLs) about the treatment landscape for epilepsy, and several physicians thought lorcaserin could offer a better safety profile than Fintepla given its more precise mode of action as a selective serotonin 2C receptor agonist (see – Spotlight On: Emerging epilepsy drugs to watch).It's the second major setback for lorcaserin across its decades-long development history. Approved by the FDA as Belviq in 2012 as a weight-loss aid, lorcaserin was withdrawn from markets in 2020 due to an increased occurrence of cancer.

Drug ApprovalAcquisitionPhase 3

17 Nov 2024

·endpts.com

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Eisai has stopped the Phase 3 clinical development of an adjunctive treatment for Dravet syndrome, a spokesperson confirmed to Endpoints News on Friday afternoon. The Tokyo drugmaker terminated the late-stage trial of lorcaserin this week, according to an update to the federal clinical trials database. The medicine, which has FDA orphan drug designation, was still listed on Eisai’s public pipeline as of Nov. 8. Dravet, a rare disorder, leads to epilepsy and affects people starting in infancy. “As other FDA-approved therapies have become available to treat this complex condition, recruiting patients for an investigational therapy has been exceedingly challenging,” the Eisai spokesperson said in an email. They said the decision wasn’t related to safety issues. Eisai got the oral drug from Arena Pharmaceuticals and marketed it as Belviq for obesity. But in 2020, the FDA requested that Eisai pull the drug after concerns about cancer outweighed its benefits. The drug is a 5-HT2C agonist that selectively activates serotonin 2C receptors in the brain. The goal is to suppress seizures in patients with Dravet syndrome. Another drugmaker developing a 5-HT2C superagonist, Longboard Pharmaceuticals, entered Phase 3 in Dravet patients this fall. Lundbeck is buying Longboard for $2.6 billion in cash. Bright Minds Biosciences is also developing a related drug and is in mid-stage testing in rare epilepsies, with preclinical work in obesity, as well. Stoke Therapeutics, Jazz Pharmaceuticals and other companies are also working in Dravet. Takeda’s drug failed a Phase 3 this summer.

Phase 3Orphan Drug

16 Oct 2024

·www.globenewswire.com

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly’s advanced AI BNA technology analysis platformTORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced collaborating with Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, to analyze the data from its first-in-human Phase 1 study of its lead compound, BMB-101. The study demonstrated positive results of the qEEG (Quantitative Electroencephalogram) data. During the EEG recording, subjects were seated with a U.S. Food and Drug Administration (FDA)- approved 19 electrode EEG headset provided by Firefly strategic partner, Zeto™ Inc. Channels were sampled at 250 or 500 Hz and referenced to A1/A2 channels (linked-ears reference) during recording. The EEG recording time was 10 minutes (~5 minutes resting with eyes closed and ~5 minutes resting with eyes open). There were four EEG recording timepoints: day 1 pre-dose (immediately before dosing) and post-dose (1h after dosing), and day 7 pre-dose and post-dose. Data was analyzed using the FireFly Neuroscience advanced EEG analysis platform. “Our artificial intelligence platform has tremendous value for the advancement and insight of clinical studies,” said Jon Olsen, CEO of Firefly. “We are pleased to have successfully collaborated with Bright Minds to analyze the data of their phase 1 study and look forward to working closely with their team once again as well as other leading biotechnology companies.” “The positive topline findings from our recently completed Phase 1 study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate. BMB-101 is clearly [getting into the brain/achieving brain penetration] and activating the target receptors as we had predicted, setting us up for potential success in a number of indications that have been validated with the 5-HT2C mechanism. With this study complete, BMB-101 is now a Phase 2 ready asset, and we intend to move forward with an investigative new drug submission immediately,” stated Ian McDonald, CEO of Bright Minds. About FireflyFirefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome. Please visit https://fireflyneuro.com/ for more information. About BMB-101BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, has demonstrated compelling activity in a host of in vitro and in vivo nonclinical tests. Compared to Lorcaserin, BMB-101 exhibits strong Gq biased signaling, coupled with minimal beta-arrestin recruitment. Bright Minds believes that G-protein biased signaling translates to better tolerance profile for this second-generation 5-HT2C agonist, making BMB-101 a best-in-class 5-HT2C agonist. Mechanistically, Serotonin (5-Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behaviors and the modulation of the behavioral effects of psychostimulants, opioids, alcohol, and nicotine. Results of clinical trials and animal studies indicate that 5-HT2C receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use. BMB-101 is a new chemical entity (NCE) and constitutes a novel scaffold 5-HT2C agonist. 5-HT2C agonism is a well proven anticonvulsant mechanism. In translational animal models, BMB-101 demonstrated a significant reduction in both the number and intensity of epileptic seizures and is a promising candidate for the treatment of Dravet Syndrome and other epilepsies. The Phase 1 trial (NCT 05397041) has been completed and BMB-101 is now Phase 2 ready. About Bright MindsBright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as fenfluramine, psilocybin, LSD, and ibogaine. Forward-Looking StatementsCertain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA™ technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and expenses associated with the Merger and other events and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the business combination; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Firefly Neuroscience Investor ContactsKCSA Strategic CommunicationsValter Pinto / Jack Perkins(212) 896-1254Firefly@KCSA.com Firefly Neuroscience Media ContactKCSA Strategic CommunicationsRaquel Cona, Vice President(516) 779-2630Rcona@KCSA.com

Phase 1Phase 2Clinical Result

100 Deals associated with Lorcaserin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D06613	Lorcaserin Hydrochloride	A08AA11	DB04871

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Eisai, Inc.	27 Jun 2012
Obesity	US	Arena Pharmaceuticals, Inc.	27 Jun 2012
Overweight	US	Arena Pharmaceuticals, Inc.	27 Jun 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsies, Myoclonic	Phase 3	US	Eisai, Inc.	23 Sep 2020
Epilepsies, Myoclonic	Phase 3	CA	Eisai, Inc.	23 Sep 2020
Diabetes Mellitus, Type 2	Phase 3	US	Eisai, Inc.	01 Dec 2007
Lennox Gastaut Syndrome	Phase 2	US	Epygenix Therapeutics, Inc.Startup	06 Sep 2021
Smoking Cessation	Phase 2	US	Arena Pharmaceuticals, Inc.	01 Mar 2014
Drug abuse	Phase 1	CA	Eisai, Inc.	01 Dec 2008
Liver Diseases	Phase 1	US	Eisai, Inc.	01 Aug 2008
Epileptic encephalopathy	Preclinical	US	Harmony Biosciences LLC	01 Nov 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| J Clin Endocrinol Metab	Not Applicable	Weight Loss POMC peptide \| insulin \| leptin	30	Lorcaserin	(etgwcererj) = substantial decrease before WL bwzsirgvrq (hfbcedjrri ) View more	-	18 Aug 2023
NCT03192995 (TLC, CTgov)	Phase 2	Cocaine-Related Disorders	22	Cocaine metabolites+lorcaserin (Experimental)	kqyqcwspnw(zlnbclbchs) = edewtbtzsl qguibhegmk (gdocgyqbkf, qitoyvlbcg - tnrxvxkula) View more	-	14 Aug 2023
				Placebo Oral Tablet (Control)	kqyqcwspnw(zlnbclbchs) = eoygspbxeu qguibhegmk (gdocgyqbkf, mpbfiapoel - jmzbxgdijx) View more
NCT03253926 (CTgov)	Phase 1/2	Marijuana Abuse	15	Lorcaserin+Marijuana (Lorcaserin + Marijuana)	jrxrnhgzdk(vcwgifzifv) = nbjvsdfkdp uramtumbys (qxudsntycl, repapxsdwr - pbkvzbkgsx) View more	-	26 Jul 2022
				Placebo+Marijuana (Placebo + Marijuana)	jrxrnhgzdk(vcwgifzifv) = owromgajpt uramtumbys (qxudsntycl, thsutqztad - rombzsucmx) View more
NAASO2021	Not Applicable	-	-	Lorcaserin	qnynebzjyi(qspippzrqj): HR = 0.91 (95% CI, 0.76 - 1.09)	-	06 Dec 2021
				Phentermine-topiramate
NCT03353220 (CTgov)	Phase 4	Weight Loss \| Obesity	32	placebo+Belviq (Placebo)	qgtdpbwzmn(fbgqoglnjj) = elqnqnhxoa rkgqkzghhf (clzcofvica, mglvsxsqbi - lhqexjhtmm) View more	-	23 Sep 2021
				Lorcaserin (Lorcaserin)	qgtdpbwzmn(fbgqoglnjj) = gkccccxuop rkgqkzghhf (clzcofvica, hlmxydvhui - qkxzqkdwfx) View more
NCT03338296 (CTgov)	Phase 4	Weight Loss \| Obesity	278	Placebo	mhadoyhmym(qbubzwwxsx) = krswlktodj yulkbsxfcv (gxouhmbgzl, nnhfioudac - ibdzqaltpq) View more	-	19 Jul 2021
NCT02537873 (Pubmed \| Front Psychiatry) Manual	Phase 1	Cocaine-Related Disorders	25	Cocaine+Lorcaserin Hydrochloride	zndpwudnfn(stpbfdtfga) = There were no significant interactions between cocaine and lorcaserin on cardiovascular measures, plasma cocaine, or subjective ratings. tmgodduoxw (gdiedpgryb ) View more	Negative	02 Jul 2021
				Cocaine+Placebo
NCT02412631 (CTgov)	Phase 2/3	Smoking Cessation \| Obesity \| Weight Gain	84	Placebo+Varenicline (Varenicline Plus Placebo)	kycanaonyt(vpljfdkrpg) = onxnrnffde jmyaaumtfz (gfnjnlbwkp, kxgzczunty - zotkmxyrlk) View more	-	10 Jun 2021
				Varenicline+lorcaserin (Varenicline Plus Lorcaserin)	kycanaonyt(vpljfdkrpg) = nxpfwxgoco jmyaaumtfz (gfnjnlbwkp, fvsieszssy - bzhofpqczn) View more
NCT02796144 (MELT, CTgov)	Phase 4	Weight Loss \| Schizoaffective disorder \| Schizophrenia ... View more	71	Lorcaserin+Metformin (Lorcaserin and Metformin)	lpjlwrzsam(flcbmozumc) = tcjaotxldl jxawryywsd (ayniavlyzq, zitnfwueef - ygvnqikcqc) View more	-	05 Feb 2021
				Placebo (Placebo)	lpjlwrzsam(flcbmozumc) = hbrmantgej jxawryywsd (ayniavlyzq, lpfkdaixqr - nzeuxvlewa) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis